Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [Springer Nature]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
无心的荆完成签到 ,获得积分10
刚刚
1秒前
123完成签到,获得积分10
1秒前
Dean应助wang采纳,获得50
1秒前
1秒前
Ava应助Rose采纳,获得10
2秒前
浩whu完成签到,获得积分10
2秒前
2秒前
wst发布了新的文献求助10
3秒前
3秒前
万安安发布了新的文献求助10
3秒前
酷波er应助constant采纳,获得10
4秒前
4秒前
王诗翔完成签到,获得积分10
4秒前
LLin应助单纯幻莲采纳,获得150
4秒前
隐形曼青应助单纯幻莲采纳,获得10
4秒前
花砸发布了新的文献求助10
5秒前
5秒前
luckyhan发布了新的文献求助10
5秒前
蓝色花生豆完成签到,获得积分0
5秒前
七七八八发布了新的文献求助10
6秒前
量子星尘发布了新的文献求助10
6秒前
6秒前
AAA陈发布了新的文献求助10
6秒前
七大洋的风完成签到,获得积分10
8秒前
8秒前
8秒前
Orange应助Mxxxc采纳,获得10
8秒前
9秒前
充电宝应助慢羊羊采纳,获得10
9秒前
qks完成签到 ,获得积分10
9秒前
万安安完成签到,获得积分10
9秒前
10秒前
科研通AI6.1应助~~~~采纳,获得80
10秒前
js完成签到,获得积分10
10秒前
10秒前
星辰大海应助沉默天宇采纳,获得10
11秒前
Zq发布了新的文献求助10
11秒前
迷人浩宇完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Short-Wavelength Infrared Windows for Biomedical Applications 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6060743
求助须知:如何正确求助?哪些是违规求助? 7893090
关于积分的说明 16304360
捐赠科研通 5204715
什么是DOI,文献DOI怎么找? 2784535
邀请新用户注册赠送积分活动 1767078
关于科研通互助平台的介绍 1647334